# Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing

> **NCT05084222** · PHASE4 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 180 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Buventol® Easyhaler® 200 µg/inhalation dmDPI
- **DRUG:** Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI
- **DRUG:** Ventoline® Evohaler® 100 µg/inhalation pMDI

## Key facts

- **NCT ID:** NCT05084222
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-11
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084222, "Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05084222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*